CKD Chapter Two Chronic kidney disease identified in

Distribution of period prevalent general Medicare (age 65+) & Market. Scan (age 50– 64)

Descriptive parameters of CKD datasets, by age, gender, race, ethnicity, comorbidity, & occupation, 2008

Incidence of recognized CKD, by U. S. Census Region & dataset, 2008 Figure 2.

Prevalence of recognized CKD, by U. S. Census Region & dataset, 2008 Figure 2.

Incidence of recognized CKD, by year & dataset Figure 2. 4 (Volume 1) Prevalent

Incidence of recognized CKD, by age & dataset, 2008 Figure 2. 5 (Volume 1)

Incidence of recognized CKD, by gender & dataset, 2008 Figure 2. 6 (Volume 1)

Prevalence of recognized CKD, by year & dataset, 2008 Figure 2. 7 (Volume 1)

Prevalence of recognized CKD, by age & dataset, 2008 Figure 2. 8 (Volume 1)

Prevalence of recognized CKD, by gender & dataset, 2008 Figure 2. 9 (Volume 1)

Stages of incident CKD as defined by the new diagnosis codes: Medicare patients age

Trends in CKD incidence: Medicare patients age 65 & older, by race Figure 2.

Stages of incident CKD as defined by the new diagnosis codes: Market. Scan patients

Stages of incident CKD as defined by the new diagnosis codes: Ingenix i 3

Stages of prevalent CKD as defined by the new diagnosis codes: Medicare patients age

Trends in CKD prevalence: Medicare patients age 65 & older, by race Figure 2.

Stages of prevalent CKD as defined by the new diagnosis codes: Market. Scan patients

Stages of prevalent CKD as defined by the new diagnosis codes: Ingenix i 3

Comorbidity in the recognized CKD population, by CKD diagnosis code & race (percent), 2008

Prevalence of diabetes, by diagnosis code, race, & year Table 2. 18 (Volume 1)

Prevalence of hypertension, by diagnosis code, race, & year Table 2. 19 (Volume 1)

Comorbidity in the non-CKD & recognized CKD populations, by GFR estimation method: Ingenix i

e. GFR, by CKD diagnosis code & GFR estimation method: Ingenix i 3 patients,

Patients with elevated uric acid levels, by CKD stage & GFR estimation method, 2008

Patients with below-normal calcium levels, by CKD stage & GFR estimation method, 2008 Figure

Patients with elevated PTH levels, by CKD stage & GFR estimation method, 2008 Figure

Patients with HDL levels below guidelines, by CKD stage & GFR estimation method, 2008

Patients with elevated triglyceride levels, by CKD stage & GFR estimation method, 2008 Figure

Patients with fasting glucose levels > normal, by CKD stage & GFR estimation method,

Slides: 30

Download presentation

CKD: Chapter Two Chronic kidney disease identified in the claims data USRDS 2010 Annual Data Report

Distribution of period prevalent general Medicare (age 65+) & Market. Scan (age 50– 64) patients with diagnosed CKD, CHF, cancer, & diabetes, 2008 Figure 2. 1 (Volume 1) Point prevalent general (fee-for-service) Medicare patients age 65 & older; point prevalent Market. Scan patients age 50– 64. CKD, CHF, cancer, & diabetes determined from claims. USRDS 2010 ADR

Descriptive parameters of CKD datasets, by age, gender, race, ethnicity, comorbidity, & occupation, 2008 Table 2. a (Volume 1) Prevalent patients surviving 2008, without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Incidence of recognized CKD, by U. S. Census Region & dataset, 2008 Figure 2. 2 (Volume 1) Prevalent patients surviving 2008, without CKD in 2007 & without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Prevalence of recognized CKD, by U. S. Census Region & dataset, 2008 Figure 2. 3 (Volume 1) Prevalent patients surviving 2008, without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Incidence of recognized CKD, by year & dataset Figure 2. 4 (Volume 1) Prevalent patients surviving cohort year, without CKD in prior year & without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Incidence of recognized CKD, by age & dataset, 2008 Figure 2. 5 (Volume 1) Prevalent patients surviving cohort year, without CKD in prior year & without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Incidence of recognized CKD, by gender & dataset, 2008 Figure 2. 6 (Volume 1) Prevalent patients surviving cohort year, without CKD in prior year & without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Prevalence of recognized CKD, by year & dataset, 2008 Figure 2. 7 (Volume 1) Prevalent patients surviving cohort year, without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Prevalence of recognized CKD, by age & dataset, 2008 Figure 2. 8 (Volume 1) Prevalent patients surviving cohort year, without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Prevalence of recognized CKD, by gender & dataset, 2008 Figure 2. 9 (Volume 1) Prevalent patients surviving cohort year, without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Stages of incident CKD as defined by the new diagnosis codes: Medicare patients age 65 & older, by race Figure 2. 10 (Volume 1) Prevalent patients surviving cohort year, without CKD in prior year & without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Trends in CKD incidence: Medicare patients age 65 & older, by race Figure 2. 11 (Volume 1) Prevalent patients surviving cohort year, without CKD in prior year & without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Stages of incident CKD as defined by the new diagnosis codes: Market. Scan patients age 20– 64 Figure 2. 12 (Volume 1) Prevalent patients surviving cohort year, without CKD in prior year & without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Stages of incident CKD as defined by the new diagnosis codes: Ingenix i 3 patients age 20– 64 Figure 2. 13 (Volume 1) Prevalent patients surviving cohort year, without CKD in prior year & without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Stages of prevalent CKD as defined by the new diagnosis codes: Medicare patients age 65 & older, by race Figure 2. 14 (Volume 1) Prevalent patients surviving cohort year, without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Trends in CKD prevalence: Medicare patients age 65 & older, by race Figure 2. 15 (Volume 1) Prevalent patients surviving cohort year, without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Stages of prevalent CKD as defined by the new diagnosis codes: Market. Scan patients age 20– 64 Figure 2. 16 (Volume 1) Prevalent patients surviving cohort year, without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Stages of prevalent CKD as defined by the new diagnosis codes: Ingenix i 3 patients age 20– 64 Figure 2. 17 (Volume 1) Prevalent patients surviving cohort year, without ESRD, age 65 & older (Medicare) & 20– 64 (Market. Scan & Ingenix i 3). USRDS 2010 ADR

Comorbidity in the recognized CKD population, by CKD diagnosis code & race (percent), 2008 Table 2. b (Volume 1) Medicare patients age 65 & older, surviving all of 2008; ESRD patients excluded. USRDS 2010 ADR

Prevalence of diabetes, by diagnosis code, race, & year Table 2. 18 (Volume 1) Medicare patients age 65 & older, surviving all of 2008; ESRD patients excluded. USRDS 2010 ADR

Prevalence of hypertension, by diagnosis code, race, & year Table 2. 19 (Volume 1) Medicare patients age 65 & older, surviving all of 2008; ESRD patients excluded. USRDS 2010 ADR

Comorbidity in the non-CKD & recognized CKD populations, by GFR estimation method: Ingenix i 3 patients, 2008 Table 2. c (Volume 1) *Claims-based comorbidities. **Defined from laboratory values. Elevated uric acid defined as ≥ 7 mg/dl for males & ≥ 6 mg/dl for females. Abnormality of uric acid & parathyroid hormone defined by ≥ 95 th percentile, NHANES data. Abnormality of calcium defined by ≤ 5 th percentile, NHANES data. Abnormality of glucose based on normal range, Ingenix i 3 data. WHO anemia defined as hemoglobin <13 g/dl in males, <12 g/dl in females. Elevated triglycerides ≥ 150 mg/dl; reduced HDL (“good”) cholesterol: males <40 mg/dl; females <50 mg/dl; based on criteria proposed by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III). Prevalent Ingenix i 3 patients age 20– 64, surviving all of 2008; ESRD patients excluded. USRDS 2010 ADR

e. GFR, by CKD diagnosis code & GFR estimation method: Ingenix i 3 patients, 2008 Figure 2. 20 (Volume 1) Prevalent Ingenix i 3 patients age 20– 64, 2008; error bars represent the 25 th & 75 th percentiles. ESRD patients excluded. USRDS 2010 ADR

Patients with elevated uric acid levels, by CKD stage & GFR estimation method, 2008 Figure 2. 21 (Volume 1) Prevalent Ingenix i 3 patients age 20– 64, 2008; ESRD patients excluded. See footnote to Table 2. c for definitions. USRDS 2010 ADR

Patients with below-normal calcium levels, by CKD stage & GFR estimation method, 2008 Figure 2. 22 (Volume 1) Prevalent Ingenix i 3 patients age 20– 64, 2008; ESRD patients excluded. See footnote to Table 2. c for definitions. USRDS 2010 ADR

Patients with elevated PTH levels, by CKD stage & GFR estimation method, 2008 Figure 2. 23 (Volume 1) Prevalent Ingenix i 3 patients age 20– 64, 2008; ESRD patients excluded. See footnote to Table 2. c for definitions. USRDS 2010 ADR

Patients with HDL levels below guidelines, by CKD stage & GFR estimation method, 2008 Figure 2. 24 (Volume 1) Prevalent Ingenix i 3 patients age 20– 64, 2008; ESRD patients excluded. See footnote to Table 2. c for definitions. USRDS 2010 ADR

Patients with elevated triglyceride levels, by CKD stage & GFR estimation method, 2008 Figure 2. 25 (Volume 1) Prevalent Ingenix i 3 patients age 20– 64, 2008; ESRD patients excluded. See footnote to Table 2. c for definitions. USRDS 2010 ADR

Patients with fasting glucose levels > normal, by CKD stage & GFR estimation method, 2008 Figure 2. 26 (Volume 1) Prevalent Ingenix i 3 patients age 20– 64, 2008; ESRD patients excluded. See footnote to Table 2. c for definitions. USRDS 2010 ADR